1015242-03-1 Usage
General Description
1-BENZYL-4-[5-(4,4,5,5-TETRAMETHYL-[1,3,2]-DIOXABOROLAN-2-YL)PYRIDIN-2-YL]PIPERAZINE is a chemical compound that contains a piperazine ring as well as a boron-containing heterocycle. 1-BENZYL-4-[5-(4,4,5,5-TETRAMETHYL-[1,3,2]-DIOXABOROLAN-2-YL)PYRIDIN-2-YL]PIPERAZINE is a complex organic molecule with potential applications in medicinal chemistry and drug development. The presence of the boron-containing moiety suggests that this compound may have unique chemical properties and could potentially be used as a pharmacophore in the design of novel therapeutic agents. Additionally, the presence of the benzyl and pyridine groups suggests that this compound may have the ability to interact with biological targets and could potentially be used as a lead compound for the development of new pharmaceuticals. However, the specific biological activity and potential applications of this compound would need to be further investigated through experimental studies.
Check Digit Verification of cas no
The CAS Registry Mumber 1015242-03-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,1,5,2,4 and 2 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1015242-03:
(9*1)+(8*0)+(7*1)+(6*5)+(5*2)+(4*4)+(3*2)+(2*0)+(1*3)=81
81 % 10 = 1
So 1015242-03-1 is a valid CAS Registry Number.
InChI:InChI=1/C22H30BN3O2/c1-21(2)22(3,4)28-23(27-21)19-10-11-20(24-16-19)26-14-12-25(13-15-26)17-18-8-6-5-7-9-18/h5-11,16H,12-15,17H2,1-4H3
1015242-03-1Relevant articles and documents
SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
-
Paragraph 001216; 001217; 001218, (2018/04/27)
Provided herein are compounds of the Formula I and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
